Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience

Autor Tong, Daniel, Wang, Lei, Mendis, Jeewaka, Essapen, Sharadah
Vydáno v Curr Oncol (2021)

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule t...

Autor Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan M., Modjtahedi, Helmout
Vydáno v Int J Oncol (2016)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

Autor Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Vydáno v Br J Cancer (2015)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal can...

Autor Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan, Modjtahedi, Helmout
Vydáno v Oncotarget (2016)

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival

Autor Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan Michael, Modjtahedi, Helmout
Vydáno 2014

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer

Autor Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M., Modjtahedi, Helmout
Vydáno v Oncotarget (2019)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

Autor Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M., Modjtahedi, Helmout
Vydáno v Cancers (Basel) (2021)

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

Autor Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan, Modjtahedi, Helmout
Vydáno v Oncotarget (2018)

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

Autor Gollins, Simon, West, Nick, Sebag-Montefiore, David, Myint, Arthur Sun, Saunders, Mark, Susnerwala, Shabbir, Quirke, Phil, Essapen, Sharadah, Samuel, Leslie, Sizer, Bruce, Worlding, Jane, Southward, Katie, Hemmings, Gemma, Tinkler-Hundal, Emma, Taylor, Morag, Bottomley, Daniel, Chambers, Philip, Lawrie, Emma, Lopes, Andre, Beare, Sandy
Vydáno v Br J Cancer (2017)

Objective responses to first-line neoadjuvant carboplatin−paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of...

Autor Morgan, Robert D, McNeish, Iain A, Cook, Adrian D, James, Elizabeth C, Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M, Krell, Jonathan, Parkinson, Christine, Poole, Christopher J, Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C, Ledermann, Jonathan A, Clamp, Andrew R
Vydáno v Lancet Oncol (2021)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Autor Iveson, Timothy J, Kerr, Rachel S, Saunders, Mark P, Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S, Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, Paul, James
Vydáno v Lancet Oncol (2018)

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Autor Robles-Zurita, José, Boyd, Kathleen A., Briggs, Andrew H., Iveson, Timothy, Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Segelov, Eva, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Pearson, Sarah, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Hughes, Rob, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, Paul, James
Vydáno v Br J Cancer (2018)

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Autor Iveson, Timothy, Boyd, Kathleen A, Kerr, Rachel S, Robles-Zurita, Jose, Saunders, Mark P, Briggs, Andrew H, Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Pearson, Sarah, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S, Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet, Paul, James
Vydáno v Health Technol Assess (2019)